The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

BACKGROUND: Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate‐to‐severe psoriasis. OBJECTIVE: Evaluate efficacy and safety of apremilast vs. placebo in biologic‐naive patients with moderate‐to‐severe plaque psoriasis and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R.M., Goncalves, J., Shah, K., Piguet, V., Soung, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363370/
https://www.ncbi.nlm.nih.gov/pubmed/27768242
http://dx.doi.org/10.1111/jdv.14015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363370/
https://www.ncbi.nlm.nih.gov/pubmed/27768242
http://dx.doi.org/10.1111/jdv.14015

Ejemplares similares